Nottingham cancer detection company secures £10m investment
Nottingham early cancer detection company Oncimmune has announced its entry into the Chinese market after signing an agreement with a Hong Kong-based counterpart.
Genostics will market Oncimmune's EarlyCDT technology in China, where cancer is the number one killer of both and women, with over 700,000 cases diagnosed annually.
Oncimmune says the deal will net it £15.7m in the first six years of post-market entry, and £5m a year after that.
As part of the deal, Genostics will invest £10m into Oncimmune by buying shares in th... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
